Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder

References

• Dydyk AM, Jain NK, Gupta M. Opioid use disorder. In: StatPearls [Internet]. StatPearls Publishing; 2022.
   Google Scholar
• Taylor JL, Samet JH. Opioid use disorder. Ann Intern Med. 2022;175:ITC1–16.
   PubMed Web of Science ®Google Scholar
• Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741–1748. doi:10.1213/ANE.0000000000002496
   PubMed Web of Science ®Google Scholar
• Haley DF, Saitz R. The opioid epidemic during the COVID-19 pandemic. JAMA. 2020;324:1615–1617. doi:10.1001/jama.2020.18543
   PubMed Web of Science ®Google Scholar
• Rinaldi R, Bersani G, Marinelli E, Zaami S. The rise of new psychoactive substances and psychiatric implications: a wide-ranging, multifaceted challenge that needs far‐reaching common legislative strategies. Hum Psychopharmacol Clin Exp. 2020;35:e2727.
   PubMed Web of Science ®Google Scholar
• Pichini S, Zaami S, Pacifici R, Tagliabracci A, Busardò FP. The challenge posed by new synthetic opioids: pharmacology and toxicology. Front Pharmacol. 2019;563. doi:10.3389/fphar.2019.00563
   Google Scholar
• Lo Faro AF, Berardinelli D, Cassano T, et al. New psychoactive substances intoxications and fatalities during the COVID-19 epidemic. Biology. 2023;12:273. doi:10.3390/biology12020273
   PubMedGoogle Scholar
• Amaducci A, Aldy K, Campleman SL, et al. Naloxone use in novel potent opioid and fentanyl overdoses in emergency department patients. JAMA Network Open. 2023;6(8):e2331264–e2331264. doi:10.1001/jamanetworkopen.2023.31264
   PubMed Web of Science ®Google Scholar
• Coffa D, Snyder H. Opioid use disorder: medical treatment options. Am Fam Physician. 2019;100:416–425.
   PubMed Web of Science ®Google Scholar
• Yarmolinsky A, Rettig RA. Federal regulation of methadone treatment; 1995.
   Google Scholar
• Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology. 1995;13:269–293. doi:10.1016/0893-133X(95)00140-9
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. doi:10.1002/14651858.CD002209.pub2
   PubMed Web of Science ®Google Scholar
• Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567–580. doi:10.1007/s40263-019-00637-z
   PubMed Web of Science ®Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial:: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–352. doi:10.1016/j.jsat.2010.07.009
   PubMed Web of Science ®Google Scholar
• Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (update); 2017.
   Google Scholar
• Feng H, Elladki R, Jiang J, Wei G-W. Machine-learning analysis of opioid use disorder informed by MOR, DOR, KOR, NOR and ZOR-based interactome networks. Comput Biol Med. 2023;157:106745. doi:10.1016/j.compbiomed.2023.106745
   PubMed Web of Science ®Google Scholar
• Younger J, Noor N, McCue R, Mackey S. Low‐dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double‐blind, placebo‐controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529–538. doi:10.1002/art.37734
   PubMed Web of Science ®Google Scholar
• Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine–naloxone in the treatment of opioid dependence. Expert Opin Pharmacother. 2009;10(15):2537–2544. doi:10.1517/14656560903213405
   PubMed Web of Science ®Google Scholar
• Strang J, McDonald R, Campbell G, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395–1418. doi:10.1007/s40265-019-01154-5
   PubMed Web of Science ®Google Scholar
• NIDA. How much does opioid treatment cost? 2023. Available from: https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/how-much-does-opioid-treatment-cost. Accessed March 19, 2024.
   Google Scholar
• Goldfine CE, Tom JJ, Im DD, et al. The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Front Psychiatry. 2023;14:1141836. doi:10.3389/fpsyt.2023.1141836
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900. doi:10.1001/jama.2014.3628
   PubMed Web of Science ®Google Scholar
• Fan AZ, Chou SP, Zhang H, Jung J, Grant BF. Prevalence and correlates of past-year recovery from DSM-5 alcohol use disorder: results from national epidemiologic survey on alcohol and related conditions-III. Alcohol Clin Exp Res. 2019;43:2406–2420. doi:10.1111/acer.14192
   PubMed Web of Science ®Google Scholar
• Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. 2014;79–88. doi:10.15288/jsads.2014.s17.79
   PubMedGoogle Scholar
• Grosshans M, Mutschler J, Kiefer F. Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience. Int Clin Psychopharmacol. 2015;30(4):237–238. doi:10.1097/YIC.0000000000000069
   PubMed Web of Science ®Google Scholar
• Wang DS, Sternbach G, Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J Emerg Med. 1998;16(3):471–475. doi:10.1016/S0736-4679(98)00019-5
   PubMedGoogle Scholar
• Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303–312. doi:10.1176/appi.ajp.163.2.303
   PubMed Web of Science ®Google Scholar
• Dhawan BN, Cesselin F, Raghubir R, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 1996;48(4):567–592.
   PubMed Web of Science ®Google Scholar
• Potter DN, Damez-Werno D, Carlezon WA Jr, Cohen BM, Chartoff EH. Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry. 2011;70(8):744–753. doi:10.1016/j.biopsych.2011.05.021
   PubMed Web of Science ®Google Scholar
• Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73. doi:10.1016/j.brainres.2009.09.074
   PubMed Web of Science ®Google Scholar
• Woods JH, Medzihradsky F, Smith CB, Butelman ER, Winger G. Evaluation of new compounds for opioid activity (1996). Probl Drug Depend. 1997;396:1.
   Google Scholar
• Wang D, Raehal KM, Bilsky EJ, Sadée W. Inverse agonists and neutral antagonists at µ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem. 2001;77:1590–1600. doi:10.1046/j.1471-4159.2001.00362.x
   PubMed Web of Science ®Google Scholar
• Kyhl LB, Li S, Faerch KU, Soegaard B, Larsen F, Areberg J. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ‐opioid receptor occupancy. Br J Clin Pharmacol. 2016;81:290–300. doi:10.1111/bcp.12805
   PubMed Web of Science ®Google Scholar
• Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988;29:1207–1211.
   PubMed Web of Science ®Google Scholar
• Rabiner EA, Beaver J, Makwana A, et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011;16(8):826–835. doi:10.1038/mp.2011.29
   PubMed Web of Science ®Google Scholar
• Walker BM, Koob GF. Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008;33(3):643–652. doi:10.1038/sj.npp.1301438
   PubMed Web of Science ®Google Scholar
• Schluger JH, Ho A, Borg L, et al. Nalmefene causes greater hypothalamic‐pituitary‐adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res. 1998;22:1430–1436. doi:10.1111/j.1530-0277.1998.tb03931.x
   PubMed Web of Science ®Google Scholar
• Jacobson ML, Browne CA, Lucki I. Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annu Rev Pharmacol Toxicol. 2020;60(1):615–636. doi:10.1146/annurev-pharmtox-010919-023317
   PubMedGoogle Scholar
• Benth JŠ, Solli KK, Opheim A, et al. Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study. JAMA Psychiatry. 2019;76:127–134. doi:10.1001/jamapsychiatry.2018.3537
   PubMed Web of Science ®Google Scholar
• Hao S, Ogawa H. Naltrexone, but not atropine or yohimbine, antagonizes suppression of formalin-induced spinal sensitization by intrathecal nociceptin. Life Sci. 1998;63(11):A167–73. doi:10.1016/S0024-3205(98)00359-2
   Web of Science ®Google Scholar
• Meeting C on P of DD (U. S). S, Abuse NI on D. Problems of Drug Dependence: proceedings of the. Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc [Internet]. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse; 1997. Available from: https://books.google.com/books?id=hgj5eTyGTI4C. Accessed March 19, 2024.
   Google Scholar
• Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R. Harms associated with taking nalmefene for substance use and impulse control disorders: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2017;12:e0183821.
   PubMed Web of Science ®Google Scholar
• Gual A, He Y, Torup L, van den Brink W, Mann K; Group E 2 S. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432–1442. doi:10.1016/j.euroneuro.2013.02.006
   PubMed Web of Science ®Google Scholar
• Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–713. doi:10.1016/j.biopsych.2012.10.020
   PubMed Web of Science ®Google Scholar
• van den Brink W, Sørensen P, Torup L, Mann K, Gual A, Group SS. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014;28:733–744. doi:10.1177/0269881114527362
   PubMed Web of Science ®Google Scholar
• Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med. 1993;22(2):187–190. doi:10.1016/S0196-0644(05)80200-8
   PubMed Web of Science ®Google Scholar
• Sarkar S, Addagadda SS, Bhatia G, Chadda RK. Adverse drug reactions with naltrexone: experience from an addiction treatment center. Indian J Psychiatry. 2021;63(2):206–207. doi:10.4103/psychiatry.IndianJPsychiatry_94_20
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. LiverTox: a website on drug-induced liver injury. In: Drug-induced liver disease. Elsevier. 2013;725–732.
   Google Scholar
• Niciu MJ, Arias AJ. Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs. 2013;27(10):777–787. doi:10.1007/s40263-013-0096-4
   PubMed Web of Science ®Google Scholar
• Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1994;56(2):45–50. doi:10.1016/0024-3205(94)00937-6
   Web of Science ®Google Scholar
• Wang S. Historical review: opiate addiction and opioid receptors. Cell Transplant. 2019;28:233–238. doi:10.1177/0963689718811060
   PubMed Web of Science ®Google Scholar
• Walwyn WM, Miotto KA, Evans CJ. Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions. Drug Alcohol Depend. 2010;108(3):156–165. doi:10.1016/j.drugalcdep.2010.01.001
   PubMed Web of Science ®Google Scholar
• Gelfman LP, Chai EJ. Chapter 8 - What Special Considerations Should Guide the Safe Use of Methadone? In: Goldstein NE, Morrison RS, editors. Evidence-Based Practice in Palliative Medicine [Internet]. Philadelphia: W.B. Saunders; 2013:39–43.
   Google Scholar
• Davis MP. Methadone does not block NMDA receptors. J Pain Symptom Manage. 2021;62(3):e7–8. doi:10.1016/j.jpainsymman.2021.05.014
   PubMed Web of Science ®Google Scholar
• Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity. J Med Toxicol. 2018;14(4):306–322. doi:10.1007/s13181-018-0685-1
   PubMed Web of Science ®Google Scholar
• Yokell M A, Zaller N D, Green T C, Rich J D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28–41. doi:10.2174/1874473711104010028
   PubMedGoogle Scholar
• Serafini G, Adavastro G, Canepa G, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19(8):2410. doi:10.3390/ijms19082410
   PubMed Web of Science ®Google Scholar
• Pande LJ, Arnet RE, Piper BJ. An examination of the complex pharmacological properties of the non-selective opioid modulator buprenorphine. Pharmaceuticals. 2023;16(10):1397. doi:10.3390/ph16101397
   Web of Science ®Google Scholar
• Canestrelli C, Marie N, Noble F. Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration. Int J Neuropsychopharmacol. 2014;17:1367–1373. doi:10.1017/S146114571400025X
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers. Addiction. 2010;105:709–718. doi:10.1111/j.1360-0443.2009.02843.x
   PubMed Web of Science ®Google Scholar
• Rahimi‐Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi‐Nooraie R, Amin‐Esmaeili M. Pharmacological therapies for management of opium withdrawal. Cochrane Database Syst Rev. 2018. doi:10.1002/14651858.CD007522.pub2
   PubMed Web of Science ®Google Scholar
• Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3:45–50. doi:10.4103/0976-3147.91934
   PubMedGoogle Scholar
• VIVITROL XR [package insert]. Alkermes Inc. 2021.
   Google Scholar
• Kumar R, Viswanath O, Saadabadi A. Buprenorphine; 2017.
   Google Scholar
• BUTRANS [package insert]. Purdue Pharma LP; 2014.
   Google Scholar
• BUPRENEX [package insert]. Indivior Inc.; 2019.
   Google Scholar
• BELBUCA [package insert]. Ende Pharmaceuticals Inc.; 2015.
   Google Scholar
• Kleppner SR, Patel R, Costantini LC, McDonough J. In-vitro and in-vivo characterization of a buprenorphine delivery system. J Pharm Pharmacol. 2006;58:295–302. doi:10.1211/jpp.58.3.0002
   PubMed Web of Science ®Google Scholar
• Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31–39. doi:10.1006/abio.2002.5673
   PubMed Web of Science ®Google Scholar
• Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. J Am Soc Anesthesiologists. 2011;115:1251–1260.
   PubMed Web of Science ®Google Scholar
• Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine-and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272:505–510.
   PubMed Web of Science ®Google Scholar
• SUBLOCADE [package insert]. Indivior Inc.; 2017.
   Google Scholar
• BRIXADI [package insert]. Braeburn Inc.; 2023.
   Google Scholar
• SUBUTEX [package insert]. Reckitt Benckiser Pharmaceuticals Inc; 2011.
   Google Scholar
• BUPRENORPHINE SUBLINGUAL TABLETS [package insert]. Sun Pharmaceutical Industries Inc; 2023.
   Google Scholar
• PROBUPHINE [package insert]. Braeburn Pharmaceuticals, Inc; 2016.
   Google Scholar
• Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A. Probuphine®(buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol. 2017;7:119–134. doi:10.1177/2045125316681984
   PubMed Web of Science ®Google Scholar
• Bullingham RES, McQuay HJ, Moore A, Bennett MRD. Buprenorphine kinetics. Clin Pharmacol Ther. 1980;28:667–672. doi:10.1038/clpt.1980.219
   PubMed Web of Science ®Google Scholar
• Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL. Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug Alcohol Depend. 2013;131(3):258–262. doi:10.1016/j.drugalcdep.2012.11.014
   PubMed Web of Science ®Google Scholar
• SUBOXONE [package insert]. Indivior Inc; 2022.
   Google Scholar
• IONSYS [package insert]. Ortho McNeil Inc; 2006.
   Google Scholar
• Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11(7):1017–1023. doi:10.1111/j.1526-4637.2010.00875.x
   PubMed Web of Science ®Google Scholar
• Abstral [package insert]. Sentynl Therapeutics Inc; 2016.
   Google Scholar
• ONSOLIS [package insert]. Meda Pharmaceuticals Inc; 2011.
   Google Scholar
• FENTORA [package insert]. Cephalon Inc; 2011.
   Google Scholar
• SUBSYS [package insert]. Insys Therapeutics Inc; 2016.
   Google Scholar
• Actiq [package insert]. Abbott Laboratories; 1998.
   Google Scholar
• DURAGESIC [package insert]. Janssen Pharmaceuticals Inc; 2021.
   Google Scholar
• Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987;41(4):392–401. doi:10.1038/clpt.1987.47
   PubMed Web of Science ®Google Scholar
• Horst J, Frei‐Jones M, Deych E, Shannon W, Kharasch ED. Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Pediatr Blood Cancer. 2016;63(12):2123–2130. doi:10.1002/pbc.26207
   PubMed Web of Science ®Google Scholar
• DOLOPHINE [package insert]. Roxane Laboratories; 2014.
   Google Scholar
• METHADOSE [package insert]. Mallinckrodt Inc; 2016.
   Google Scholar
• Hain RDW. Morphine and morphine‐6‐glucuronide in the plasma and cerebrospinal fluid of children. Br J Clin Pharmacol. 1999;48(1):37–42. doi:10.1046/j.1365-2125.1999.00948.x
   PubMed Web of Science ®Google Scholar
• DURAMORPH [package insert]. Baxter Healthcare Corporation; 2007.
   Google Scholar
• MORPHINE SULFATE TABLETS [package insert]. West-Ward Pharmaceuticals Corp; 2021.
   Google Scholar
• KADIAN [package insert]. Allergan USA Inc; 2016.
   Google Scholar
• MS CONTIN [package insert]. Purdue Pharma LP; 2016.
   Google Scholar
• Booij LHDJ, Vree TB, Koppers-Hoyset H, Lagerwerf AJ. Explorative pharmacokinetic study of preoperative administration of morphine 50mg sustained-release capsules (KapanolTM to surgical patients. Clin Drug Investig. 1999;18:125–132. doi:10.2165/00044011-199918020-00005
   Web of Science ®Google Scholar
• NALMEFENE HYDROCHLORIDE [package insert]. Purdue Pharma LP; 2022.
   Google Scholar
• SELINCRO [package insert]. Elaiapharm; 2017.
   Google Scholar
• REVIA [package insert]. Duramed Pharmaceuticals Inc; 2013.
   Google Scholar
• Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single-and multiple-dose pharmacokinetics of long‐acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30:480–490. doi:10.1111/j.1530-0277.2006.00052.x
   PubMed Web of Science ®Google Scholar
• Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry. 1984;45:15–19.
   PubMed Web of Science ®Google Scholar
• Dale OLA, Hoffer C, Sheffels P, Kharasch ED. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther. 2002;72:536–545. doi:10.1067/mcp.2002.128386
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76:250–269. doi:10.1016/j.clpt.2004.05.003
   PubMed Web of Science ®Google Scholar
• Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z, Zhang H. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014;9(1):e86114. doi:10.1371/journal.pone.0086114
   PubMed Web of Science ®Google Scholar
• Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976;20(3):315–328. doi:10.1002/cpt1976203315
   PubMed Web of Science ®Google Scholar
• Mitchell MC Jr, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012;73(6):991–997. doi:10.15288/jsad.2012.73.991
   PubMed Web of Science ®Google Scholar
• Matzke GR, Frye RF, Alexander ACM, et al. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. J Clin Pharmacol. 1996;36:144–151. doi:10.1002/j.1552-4604.1996.tb04179.x
   PubMed Web of Science ®Google Scholar
• Lucchi L, Bosio A, Spano PF, Trabucchi M. Action of ethanol and salsolinol on opiate receptor function. Brain Res. 1982;232:506–510. doi:10.1016/0006-8993(82)90297-9
   PubMed Web of Science ®Google Scholar
• Hiller JM, Angel LM, Simon EJ. Multiple opiate receptors: alcohol selectively inhibits binding to delta receptors. Science. 1981;214(4519):468–469. doi:10.1126/science.6270788
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880. doi:10.1001/archpsyc.1992.01820110040006
   PubMed Web of Science ®Google Scholar
• O’malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881–887. doi:10.1001/archpsyc.1992.01820110045007
   PubMed Web of Science ®Google Scholar
• Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016;17(4):619–626. doi:10.1517/14656566.2016.1146689
   PubMed Web of Science ®Google Scholar
• Kissler JL, Sirohi S, Reis DJ, et al. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry. 2014;75(10):774–782. doi:10.1016/j.biopsych.2013.03.014
   PubMed Web of Science ®Google Scholar
• Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM. κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology. 2011;61(1–2):35–42. doi:10.1016/j.neuropharm.2011.02.012
   PubMed Web of Science ®Google Scholar
• Ingman K, Hagelberg N, Aalto S, et al. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005;30(12):2245–2253. doi:10.1038/sj.npp.1300790
   PubMed Web of Science ®Google Scholar
• Tadori Y. Pharmacological profile and clinical findings of nalmefene (Selincro®) for reducing alcohol consumption in patients with alcohol dependence. Nihon Yakurigaku Zasshi. 2020;155(2):113–119. doi:10.1254/fpj.19136
   PubMedGoogle Scholar
• van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opin Drug Saf. 2015;14(4):495–504. doi:10.1517/14740338.2015.1011619
   PubMed Web of Science ®Google Scholar
• Naudet F, Fitzgerald N, Braillon A. Nalmefene for alcohol dependence: a NICE decision? Lancet Psychiatry. 2016;3(12):1104–1105. doi:10.1016/S2215-0366(16)30356-X
   PubMed Web of Science ®Google Scholar
• Bachmutsky I, Wei XP, Kish E, Yackle K. Opioids depress breathing through two small brainstem sites. Elife. 2020;9:e52694. doi:10.7554/eLife.52694
   PubMed Web of Science ®Google Scholar
• Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol. 2020;177(2):254–265. doi:10.1111/bph.14860
   PubMed Web of Science ®Google Scholar
• Yong Z, Gao X, Ma W, Dong H, Gong Z, Su R. Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats. Eur J Pharmacol. 2014;738:153–157. doi:10.1016/j.ejphar.2014.05.044
   PubMed Web of Science ®Google Scholar
• Kaplan JL, Marx JA, Calabro JJ, et al. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med. 1999;34(1):42–50. doi:10.1016/S0196-0644(99)70270-2
   PubMed Web of Science ®Google Scholar
• Britch SC, Walsh SL. Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology. 2022;239(7):2063–2081. doi:10.1007/s00213-022-06125-5
   PubMed Web of Science ®Google Scholar
• Purdue Pharma LP. Purdue pharma introduces nalmefene HCl injection, 2mg/2mL (1mg/1mL) in the U.S. for the treatment of known or suspected overdose with natural or synthetic opioids; 2022.
   Google Scholar
• NARCAN [package insert]. Adapt Pharma Inc; 2015.
   Google Scholar
• Krieter P, Chiang CN, Gyaw S, Skolnick P, Snyder R. Pharmacokinetic interaction between naloxone and naltrexone following intranasal administration to healthy subjects. Drug Metab Dispos. 2019;47(7):690–698. doi:10.1124/dmd.118.085977
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose. United States Food and Drug Administration; 2023.
   Google Scholar
• OPVEE [package insert]. Opiant Pharm. 2023.
   Google Scholar
• Crystal R, Ellison M, Purdon C, Skolnick P. Pharmacokinetic properties of an FDA‐approved intranasal nalmefene formulation for the treatment of opioid overdose. Clin Pharmacol Drug Dev. 2023;13(1):58–69. doi:10.1002/cpdd.1312
   PubMed Web of Science ®Google Scholar
• Krieter P, Gyaw S, Crystal R, Skolnick P. Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther. 2019;371(2):409–415. doi:10.1124/jpet.118.256115
   PubMed Web of Science ®Google Scholar
• Jia Z, Chen Y, Gao T, et al. Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: a randomized double-blind controlled trial. Front Pharmacol. 2023;14:1131812. doi:10.3389/fphar.2023.1131812
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010;197(4):330–331. doi:10.1192/bjp.bp.110.078105
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238–1246. doi:10.1001/archgenpsychiatry.2011.121
   PubMed Web of Science ®Google Scholar
• Frost MC, Zhang L, Kim HM, Lin L. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Network Open. 2022;5(10):e2236298–e2236298. doi:10.1001/jamanetworkopen.2022.36298
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2). doi:10.1002/14651858.CD002207.pub4
   PubMed Web of Science ®Google Scholar
• Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193–1200. doi:10.1111/j.1360-0443.2009.02627.x
   PubMed Web of Science ®Google Scholar
• Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25:79–85. doi:10.2165/00139709-200625020-00002
   PubMedGoogle Scholar
• White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence. Drug Alcohol Depend. 2009;103(1–2):37–43. doi:10.1016/j.drugalcdep.2009.03.008
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, DeFulio A, et al. Effects of incentives for naltrexone adherence on opiate abstinence in heroin‐dependent adults. Addiction. 2017;112:830–837. doi:10.1111/add.13724
   PubMed Web of Science ®Google Scholar
• Jones HE, Johnson RE, Fudala PJ, Henningfield JE, Heishman SJ. Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug Alcohol Depend. 2000;60(1):29–37. doi:10.1016/S0376-8716(00)80005-8
   PubMed Web of Science ®Google Scholar